drugset / Trial / NCT02499159

Pain Management in Response to Exparel vs. Standard Bupivicaine

NCT02499159 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on decreasing the amount of consumed pain medications. Patients will be randomly selected to received either Exparel or standard bupivicaine injection during surgery. Patients will be followed up to assess pain levels using a visual pain scale, and to assess how much pain medication was consumed.

Timeline

Start
2014-12
Primary completion
2017-07
Completion
2017-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.25 % Other
Subject Bupivacaine Other / unclassified 20 ml Other
Subject Bupivacaine Other / unclassified 266 mg Other

Indications

No indication recorded.